CommercialCoverageMedium impact
06.02.36d, Molecular Testing for the Management of Pancreatic Cysts or Barrett's Esophagus (Independence Administrators)
Independence Blue Cross·Gastroenterology, Oncology, Pathology·Medical Policy
Effective date
Mar 5, 2025
We identified it
Jun 19, 2026
Summary
Independence Administrators has reissued their molecular testing policy for pancreatic cysts and Barrett's esophagus management. This is a policy reissuance with an effective date of March 5, 2025, but specific changes are not detailed in the summary provided.
Action Required
By March 5, 2025: Billing team should review the complete policy document at the provided URL to identify specific changes to molecular testing coverage, prior authorization requirements, or billing procedures for pancreatic cyst and Barrett's esophagus molecular testing. Update billing protocols and staff training accordingly once full policy details are reviewed.